Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Artivion Inc. (AORT) Insider Trading Activity

    Healthcare • Medical Devices • 1,500 employees

    Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

    Total Value

    -$2,267,721.47

    Total Shares

    122,237

    Average Trade Value

    -$68,718.83

    Most Active Insider

    Mackin James P

    Total Activity: $1,161,112

    Largest Single Transaction

    $455,027

    by Mackin James P on Feb 24, 2025

    30-Day Activity

    2 Transactions

    Volume: 2,100 shares
    Value: $53,141

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Director
    Mar 5, 2025 600 $15,150 600 (+100.0%) Purchase
    Director
    Mar 5, 2025 1,500 $37,991 35,659 (+4.2%) Purchase
    Svp, General Counsel
    Officer
    Feb 28, 2025 23,416 $10,000 173,215 (+13.5%) Grant
    Svp, Clinical Md Affair
    Officer
    Feb 28, 2025 18,398 $10,000 98,243 (+18.7%) Grant
    Executive Vp, CFO
    Officer
    Feb 28, 2025 34,435 $10,000 110,240 (+31.2%) Grant
    Chief Commercial Officer
    Officer
    Feb 28, 2025 24,301 $10,000 184,932 (+13.1%) Grant
    President CEO
    Officer
    Feb 28, 2025 98,524 $10,000 762,406 (+12.9%) Grant
    Vp, Chief Accounting Officer
    Officer
    Feb 28, 2025 6,297 $10,000 137,438 (+4.6%) Grant
    Vp, Chief Accounting Officer
    Officer
    Feb 24, 2025 318 $8,683 131,626 (-0.2%) Sale
    Vp, Chief Accounting Officer
    Officer
    Feb 24, 2025 485 $13,243 131,141 (-0.4%) Sale
    Svp, Clinical Md Affair
    Officer
    Feb 24, 2025 672 $18,350 81,091 (-0.8%) Sale
    Chief Commercial Officer
    Officer
    Feb 24, 2025 985 $26,896 162,666 (-0.6%) Sale
    Svp, Clinical Md Affair
    Officer
    Feb 24, 2025 470 $12,834 81,763 (-0.6%) Sale
    Svp, Clinical Md Affair
    Officer
    Feb 24, 2025 2,299 $62,776 82,233 (-2.8%) Sale
    Svp, Clinical Md Affair
    Officer
    Feb 24, 2025 1,246 $34,023 79,845 (-1.6%) Sale
    President CEO
    Officer
    Feb 24, 2025 6,812 $186,008 668,778 (-1.0%) Sale
    President CEO
    Officer
    Feb 24, 2025 4,896 $133,690 663,882 (-0.7%) Sale
    President CEO
    Officer
    Feb 24, 2025 16,664 $455,027 689,374 (-2.4%) Sale
    President CEO
    Officer
    Feb 24, 2025 13,784 $376,386 675,590 (-2.0%) Sale
    Svp, General Counsel
    Officer
    Feb 24, 2025 490 $13,380 152,259 (-0.3%) Sale
    Chief Commercial Officer
    Officer
    Feb 24, 2025 2,846 $77,713 164,242 (-1.7%) Sale
    Chief Commercial Officer
    Officer
    Feb 24, 2025 2,035 $55,568 160,631 (-1.3%) Sale
    Svp, General Counsel
    Officer
    Feb 24, 2025 810 $22,118 151,449 (-0.5%) Sale
    Svp, General Counsel
    Officer
    Feb 24, 2025 1,650 $45,055 149,799 (-1.1%) Sale
    Svp, General Counsel
    Officer
    Feb 24, 2025 2,385 $65,125 152,749 (-1.6%) Sale
    Executive Vp, CFO
    Officer
    Feb 24, 2025 3,259 $88,990 75,805 (-4.3%) Sale
    Vp, Chief Accounting Officer
    Officer
    Feb 24, 2025 814 $22,227 131,944 (-0.6%) Sale
    Chief Commercial Officer
    Officer
    Feb 24, 2025 591 $16,138 163,651 (-0.4%) Sale
    Vp, Chief Accounting Officer
    Officer
    Feb 24, 2025 1,706 $46,584 132,758 (-1.3%) Sale
    Svp, General Counsel
    Officer
    Dec 11, 2024 4,035 $122,059 157,897 (-2.6%) Sale
    Svp, General Counsel
    Officer
    Dec 11, 2024 4,035 $121,050 153,862 (-2.6%) Sale
    Vp, Chief Accounting Officer
    Officer
    Dec 6, 2024 4,329 $128,398 135,660 (-3.2%) Sale
    VP Regulatory
    Officer
    Dec 4, 2024 7,618 $228,540 33,503 (-22.7%) Sale